Neoadjuvant trial design: time for a brave new world?

The article reports on the outcome of the NOAH clinical trial in the U.S. It notes that the impact of treatment with trastuzumab in the locally advanced breast cancer (LABC) setting was evaluated in the open-label NOAH study. It also mentions the results of the study which revealed that trastuzumab treatment for locally advanced breast cancer was associated with increased complete and overall response rate and improved event-free survival.